Sheron B. Bass

Preventing Adverse Drug Events in Hospitalized Patients

R S Evans, D. Classen, S. Pestotnik, 1994, The Annals of pharmacotherapy.

O4-03-08 Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer’s disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study

S. Hendrix, G. Wilcock, J. Haworth, 2006, Alzheimer's & Dementia.